<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072553</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000340181</org_study_id>
    <secondary_id>GERCOR-OPTIMOX2-CELECOXIB-2002</secondary_id>
    <secondary_id>EU-20325</secondary_id>
    <nct_id>NCT00072553</nct_id>
  </id_info>
  <brief_title>Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin, use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may&#xD;
      stop the growth of colorectal cancer by stopping blood flow to the tumor and by blocking the&#xD;
      enzymes necessary for tumor cell growth. Combining chemotherapy with celecoxib may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining celecoxib with leucovorin,&#xD;
      fluorouracil, and oxaliplatin in treating patients who have metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with metastatic colorectal cancer treated with&#xD;
           celecoxib, leucovorin calcium, fluorouracil, and oxaliplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the time of disease control to evaluate progression-free survival in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the salvage surgery rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the duration of chemotherapy-free intervals in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive FOLFOX7 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin&#xD;
      calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1.&#xD;
      Patients also receive oral celecoxib twice daily beginning on day 1. Treatment repeats every&#xD;
      14 days for 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients with stable or responding disease stop treatment. If disease progression occurs&#xD;
      during the chemotherapy-free interval, patients receive an additional 6 courses.&#xD;
&#xD;
      Patients with responding disease after receiving at least 6 courses of chemotherapy may&#xD;
      undergo surgery. Beginning within 10 weeks after surgery, patients receive simplified LV5FU2&#xD;
      chemotherapy comprising leucovorin calcium IV over 2 hours on day 1, fluorouracil IV over 46&#xD;
      hours beginning on day 1, and oral celecoxib twice daily beginning on day 1. Treatment&#xD;
      repeats every 14 days for at least 12 courses.&#xD;
&#xD;
      Quality of life is assessed at baseline, during courses 4 and 6, and then every 2 months&#xD;
      thereafter.&#xD;
&#xD;
      Patients are followed at 1 month and then every 2 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of disease control (progression-free survival)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salvage surgery rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of chemotherapy-free intervals</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Inoperable disease (i.e., not suitable for complete carcinological surgical&#xD;
                  resection)&#xD;
&#xD;
          -  Measurable disease or nonmeasurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion at least 20 mm by conventional CT&#xD;
                  scan OR 10 mm by spiral CT scan&#xD;
&#xD;
               -  Nonmeasurable disease defined as all other lesions, including small lesions or&#xD;
                  truly nonmeasurable disease&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
          -  No exclusive bone metastases&#xD;
&#xD;
          -  No symptomatic ascites or pleural effusion not evacuated before study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No known significant bleeding disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Alkaline phosphatase less than 3 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 30 mL/min&#xD;
&#xD;
          -  No uncontrolled hypercalcemia&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No total or partial bowel obstruction&#xD;
&#xD;
          -  No active gastric or duodenal ulceration or gastrointestinal bleeding within the past&#xD;
             year&#xD;
&#xD;
          -  No active inflammatory bowel disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No peripheral sensory neuropathy&#xD;
&#xD;
          -  No known sensitivity to celecoxib, other COX-2 inhibitors, NSAIDs, salicylates, or&#xD;
             sulfonamides&#xD;
&#xD;
          -  No AIDS-related illness&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior immunotherapy for metastatic disease&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed provided the progression-free interval after&#xD;
             completion of therapy is more than 6 months in duration&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  No prior adjuvant oxaliplatin&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent chronic oral or IV corticosteroid use (i.e., 2 weeks or longer in&#xD;
             duration)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs or treatments&#xD;
&#xD;
          -  No concurrent prophylactic fluconazole&#xD;
&#xD;
          -  No concurrent chronic full-dose aspirin (at least 325 mg/day), other nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs), or other cyclooxygenase (COX)-2 inhibitors&#xD;
&#xD;
               -  Concurrent low-dose (cardioprotective) aspirin (80 mg/day or equivalent) allowed&#xD;
&#xD;
          -  No concurrent lithium&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Andre, MD</last_name>
    <role>Study Chair</role>
    <affiliation>GERCOR - Multidisciplinary Oncology Cooperative Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>André T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, Hebbar M, Postel Vinay S, Bidard FC, Louvet C, de Gramont A. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol. 2007 Jan;18(1):77-81. doi: 10.1093/annonc/mdl336. Epub 2006 Oct 9.</citation>
    <PMID>17030548</PMID>
  </results_reference>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2003</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

